Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Feb 18:8:579607.
doi: 10.3389/fped.2020.579607. eCollection 2020.

Case Report: Neonatal Unexplained HUS Treated With Complement Inhibitor Eculizumab

Affiliations
Case Reports

Case Report: Neonatal Unexplained HUS Treated With Complement Inhibitor Eculizumab

Dorottya Kelen et al. Front Pediatr. .

Abstract

Background: Hemolytic uremic syndrome (HUS) is rare in neonates. It is probably an under-recognized condition in the early postnatal period as it presents similarly to the most common perinatal asphyxia and to differentiate the two conditions is challenging. We describe the clinical presentation of a potential new subtype of neonatal HUS triggered by hypoxic-ischemic event. Our patient was successfully treated by a single dose of Eculizumab as early as at 9 days of life. Case Report: A 35-weeks infant was born with low hemoglobin and subsequently developed respiratory distress, hypotension, and acidosis. Blood transfusion was administered, acidosis corrected, neurological examination remained reassuring. Few hours later he developed renal failure, macroscopic hematuria, hemobilia, thrombocytopenia and coagulopathy refractory to platelet and fresh frozen plasma transfusions. No infection was found. Haptoglobin was non-measurable, and schistocytes present, complement factors C3, C4 and B were low, FBb increased. HUS was suspected. A single dose of Eculizumab™ was administered on day 9 of life. No genetic mutation of atypical HUS was found. He was discharged with improving renal function and developing cholestasis. Conclusion: In neonates with hemolytic anemia, thrombocytopenia, hematuria and renal failure, HUS should be suspected. In neonatal HUS Eculizumab should be considered as first-line therapy and discontinuation can be considered if no genetic mutation is found and clinical condition improves. In very young patients, cholestasis could appear as potential side effect of Eculizumab™.

Keywords: case report; eculizumab; hemolytic uremic syndrome; neonatal; perinatal asphyxia.

PubMed Disclaimer

Conflict of interest statement

PS has received fees from Alexion Pharmaceuticals through his employer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Platelets and creatinine levels during the first 33 days of patient's life—Refractory thrombocytopenia and severe renal failure developed on day 2 of life. Improvements have been observed after administration of Eculizumab on day 9 of life. FFP, Fresh frozen plasma.

References

    1. Biran V, Fau S, Jamal T, Veinberg F, Renolleau S, Gold F, et al. . Perinatal asphyxia may present with features of neonatal atypical hemolytic uremic syndrome. Pediatr Nephrol. (2007) 12:2129–32. 10.1007/s00467-007-0570-7 - DOI - PubMed
    1. Ulinski T, Lervat C, Ranchin B, Gillet Y, Floret D, Cochat P. Neonatal hemolytic uremic syndrome after mother-to-child transmission of Escherichia coli O157. Pediatr Nephrol. (2005) 20:1334–5. 10.1007/s00467-005-1871-3 - DOI - PubMed
    1. Azzopardi D, Brocklehurst P, Edwards D, Halliday H, Levene M, The TOBY Study Group et al. . Whole body hypothermia for the treatment of perinatal asphyxial encephalopathy. A randomised controlled trial. BMC Pediatr. (2008) 8:17. 10.1186/1471-2431-8-17 - DOI - PMC - PubMed
    1. Anastaze Stelle K, Gonzalez E, Wilhelm-Bals Michelet PR, Korff CM, Parvex P. Successful treatment of neonatal atypical haemolytic uremic syndrome with C5 monoclonal antibody. Arch Pédiatr. (2016) 23:283–6. 10.1016/j.arcped.2015.11.020 - DOI - PubMed
    1. Besbas N, Gulhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, et al. . Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol. (2013) 28:155–8. 10.1007/s00467-012-2296-4 - DOI - PubMed

Publication types

LinkOut - more resources